Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma

被引:23
作者
Moug, Susan J.
Leen, Edward
Horgan, Paul G.
Imrie, Clement W.
机构
[1] Univ Glasgow, Glasgow Royal Infirm, Dept Surg, Glasgow G31 2ER, Lanark, Scotland
[2] Univ Glasgow, Glasgow Royal Infirm, Dept Radiol, Glasgow G31 2ER, Lanark, Scotland
关键词
islet cell tumours; VIPoma; hepatic metastases; biochemical abnormalities; radiofrequency ablation;
D O I
10.1159/000090257
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Vasoactive intestinal peptide-secreting tumours (VIPomas) are rare islet cell tumours of the pancreas that can result in life-threatening biochemical abnormalities. The optimal intervention for metastatic VIPoma remains undecided. This case history documents the clinical role of radiofrequency (RF) ablation in the treatment of metastatic VIPoma. Case History: A primary pancreatic VIPoma was diagnosed in a 61-year-old female in 1998 and a distal pancreatectomy and splenectomy were performed. She remained disease-free for 44 months when she presented as an emergency with watery diarrhoea, hypokalaemia, renal failure and an elevated serum VIP level. CT scanning showed a liver metastasis and open RF ablation was performed with complete resolution of symptoms and biochemistry within 48 h. Post-ablation imaging confirmed complete ablation of the metastasis. She remained disease-free until 22 months later when watery diarrhoea resumed and a new hepatic metastasis was seen on CT. Percutaneous RF ablation was performed and follow-up CT scan showed complete ablation of the metastasis. The patient remains disease- and symptom-free 10 months after the second RF ablation. Conclusion: This case illustrates that the pronounced clinical and biochemical upset caused by metastatic VIPoma can be resolved safely, quickly and repeatedly by RF ablation. Copyright (C) 2006 S. Karger AG, Basel and IAP.
引用
收藏
页码:155 / 159
页数:5
相关论文
共 16 条
[1]  
BLOOM SR, 1973, LANCET, V2, P14
[2]   Islet cell tumors of the pancreas - The medical oncologist's perspective [J].
Brentjens, R ;
Saltz, L .
SURGICAL CLINICS OF NORTH AMERICA, 2001, 81 (03) :527-+
[3]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[4]  
CAPELLA C, 1983, CANCER-AM CANCER SOC, V52, P1860, DOI 10.1002/1097-0142(19831115)52:10<1860::AID-CNCR2820521017>3.0.CO
[5]  
2-F
[6]   Adverse events during radiofrequency treatment of 582 hepatic tumors [J].
de Baère, T ;
Risse, O ;
Kuoch, V ;
Dromain, C ;
Sengel, C ;
Smayra, T ;
El Din, MG ;
Letoublon, C ;
Elias, D .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2003, 181 (03) :695-700
[7]  
DELCORE R, 1994, J AM COLL SURGEONS, V178, P187
[8]   Percutaneous sonographically guided saline-enhanced radiofrequency ablation of hepatocellular carcinoma [J].
Giorgio, A ;
Tarantino, L ;
de Stefano, G ;
Scala, V ;
Liorre, G ;
Scarano, F ;
Perrotta, A ;
Farella, N ;
Aloisio, V ;
Mariniello, N ;
Coppola, C ;
Francica, G ;
Ferraioli, G .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2003, 181 (02) :479-484
[9]   Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors [J].
Hellman, P ;
Ladjevardi, S ;
Skogseid, B ;
Åkerström, G ;
Elvin, A .
WORLD JOURNAL OF SURGERY, 2002, 26 (08) :1052-1056
[10]  
MEKHJIAN HS, 1987, SEMIN ONCOL, V14, P282